Phenotypic Heterogeneity in Chinese Patients with Hepatocyte Nuclear Factor-1Β Mutations.

Congrong Wang,Rong Zhang,Jingyi Lu,Feng Jiang,Cheng Hu,Jian Zhou,Fang Liu,Feng Zhang,Wen Qin,Mei Li,Xiaojing Ma,Jingbin Yan,Yuqian Bao,Kunsan Xiang,Weiping Jia
DOI: https://doi.org/10.1016/j.diabres.2011.10.007
IF: 8.18
2012-01-01
Diabetes Research and Clinical Practice
Abstract:Aims/hypothesis: The aim of this study was to investigate clinical spectrum of hepatocyte nuclear factor-1 beta (HNF-1 beta) mutation in Chinese diabetic patients with renal dysfunction and/or structure abnormalities.Materials and methods: A total of 104 diabetic patients with renal structural abnormalities and/or non-diabetic renal dysfunction were recruited and HNF-1 beta mutation was screened by direct sequencing.Results: Three heterozygous missense mutations including c.494G>A (p.R165H), c.662A>T (p.D221V) and c.780G>C (p.E260D) were identified. Progression of diabetes and mild decline of renal function were observed in the mutation carriers during the follow-up. The p.R165H mutation carrier had severe beta-cell dysfunction and different extrapancreatic phenotypes. Compared with type 2 diabetes and normoglycemics, the p.R165H mutation carrier had a lower basal C-peptide (0.30, 0.61 +/- 0.07 and 0.50 +/- 0.04 nmol/L for p.R165H, type 2 diabetes and normoglycemics, respectively) and low values of acute C-peptide response to arginine (0.15, 0.48 +/- 0.18 and 0.76 +/- 0.08 nmol/L for p.R165H, type 2 diabetes and normoglycemics, respectively).Conclusion: Patients with the HNF-1 beta mutation in our population can have different pancreatic and extrapancreatic phenotypes. The exact contributions of mutations to the phenotypes await functional confirmation. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
What problem does this paper attempt to address?